Author

C. Almond

Observed names: C Almond, C. M. Almond, Camille M. Almond

Institution: BresMed

Observed institutions: University of Washington Medical Center, BresMed

OpenAlex ID: A5109234655

Pigment dispersion and chronic intraocular pressure elevation after sulcus placement of 3-piece acrylic intraocular lens

2009 · Camille M. Almond, Michael C. Wu, et al. · Journal of Cataract & Refractive Surgery · 18

PSS25 the Cost-Effectiveness of Ozurdex® (Dexamethasone Intravitreal Implant in Applicator) Compared With Observation for the Treatment of Macular Oedema Following Central and Branch Retinal Vein Occlusion

2011 · E. Hayward, C. Almond, et al. · Value in Health · 3

The Estimated Survival of Patients with Double Refractory Chronic Lymphocytic Leukaemia; A Reanalysis of NICE TA202 Using Bayesian Methodology to Model Observed Data

2013 · C. Almond, J.W. Stevens, et al. · Value in Health · 2

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

2020 · G. Gourzoulidis, O. Zisimopoulou, et al. · Value in Health · 1

PRM163 The Use of Expected Value of Perfect Information Analysis Within Economic Evaluations and Health Technology Assessments in the UK

2012 · C. Almond, N.J. Brereton · Value in Health · 1

PSS26 The Use of A Mixed-Treatment Comparison to Assess the Cost-Effectiveness of Ozurdex® (Dexamethasone Intravitreal Implant in Applicator) Compared With Bevacizumab Intravitreal Injections for Patients With Macular Oedema Following Branch Retinal Vein Occlusion

2011 · C. Almond, E. Hayward, et al. · Value in Health · 1

PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal

2020 · R. Guerreiro, A.T. Paquete, et al. · Value in Health

Pns260 Inclusion of New Strategies in the Uk's Cancer Drug Fund: What Was Decided in France?

2019 · M. Trancart, C. Almond, et al. · Value in Health

The Cost-Effectiveness of Ustekinumab in Moderate to Severely Active Crohn’s Disease in Sweden

2017 · A Hansson-Hedblom, C Almond, et al. · Value in Health

Challenges to The Economic Modelling of Macular Oedema Due to Retinal Vein Occlusion And Diabetes

2015 · C Almond, N Brereton · Value in Health

Key Drivers of Cost Effectiveness In Crohn’s Disease

2015 · IE Sly, M Worbes-Cerezo, et al. · Value in Health

Mapping from SF-6D to EQ-5D: Changes in Estimates Based on the Choice of Algorithm

2014 · A.J. Hatswell, T. Ito, et al. · Value in Health

Quality of Life in Psoriatic Arthritis: Consistent and Stable Across Datasets

2014 · A.J. Hatswell, C. Almond, et al. · Value in Health

The Cost-Effectiveness of Bimatoprost 0.03%/Timolol 0.05% Preservative-Free Fixed Combination Compared with Dorzolamide/Timolol Preservative-Free Fixed Combination and 2-Bottle Unfixed Combinations for the Treatment of Primary Open-Angle Glaucoma in the United Kingdom

2013 · A. Hirst, C. Almond, et al. · Value in Health

Valutazione economica del trattamento con impianto intravitreale biodegradabile di desametasone di pazienti affetti da edema maculare secondario a occlusione della vena retinica, in Italia

2012 · J. W. Kowalski, E. Hayward, et al. · PharmacoEconomics Italian Research Articles

Works count: 15

Citation count: 26

H-index: 2

I10-index: 1